Boston, June 18th

Welcome to hubXchange’s Immuno-Oncology Xchange Boston 2024, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing immuno-oncology therapies, through a series of roundtable discussions. 
Discussion topics will cover Immune Biomarkers, Translational Research, Clinical Development, and Tumor Microenvironment.
Take advantage of this unique highly interactive meeting format designed for maximum engagement and collaboration with your peers.

Please note this is an In-Person meeting.

VENUE DETAILS: Woburn Hilton Hotel, 2 Forbes Road, Woburn, MA, 01801, US


  • Identification of specific immune biomarkers in blood for gene-edited cellular therapeutics
  • Pharmacodynamic and predictive biomarkers for IO from preclinical to clinical stages
  • Translational strategies to develop clinically safe and effective immune cell engagers
  • How to select the right translational screening model to monitor IO agents
  • Early signals of efficacy, biomarkers and confidence in early clinical I/O trials
  • How to maximize clinical success: Patient selection strategies beyond target expression
  • Exploring different cellular modalities
  • TME-targeting combinations – improving efficacy

Full Xchange Agenda

Click on each track for detailed agenda

Immune Biomarkers

Titles and Bullets
8:00 – 8:30
8:30 – 9:00

Opening Keynote Presentation

9:05 – 10:05

Identification of specific immune biomarkers in blood for gene-edited cellular therapeutics

  • What to look for and do they exist?
  • What should be the key attributes of such biomarkers?
  • What technology platform are appropriate for their identification?
  • How to develop specific assays in the absence of clinical samples?
  • What should be the biomarker characterization/validation strategies?

Lalit Kumar, Director of Clinical Bioanalytics and Translational Science at Beam Therapeutics, is currently heading implementation of biomarkers strategy in clinical trials to develop cellular therapeutics targeting T cell leukemia and Lymphoma. He brings in 10 years of clinical bioanalytical expertise and leadership in precision medicine which includes clinical assay design and development.
Before joining Beam Therapeutics, he was Associate Director of Clinical Pharmacology at CRISPR Therapeutics, leading clinical biomarkers strategies for phase I/II clinical trials for hematology and immuno-oncology pipelines, including CASGEVYTM.
As an independent investigator at Harvard medical school, he also worked on human T/B/NK cell primary immunodeficiencies.

Lalit Kumar
10:10 – 10:40
1-2-1 Meetings/Networking Break
10:40 – 11:10
1-2-1 Meetings/Networking Break
11:10 – 11:20
Morning Refreshments
11:20 – 12:20

Sponsor-led Roundtable

12:20 – 13:20
Networking Lunch
13:20 – 13:50

Spotlight Presentation

13:55 – 14:25

1-2-1 Meetings/Networking Break

14:25 – 14:55
1-2-1 Meetings/Networking Break
15:00 – 15:30

Poster Session

15:35 – 16:35

Pharmacodynamic and predictive biomarkers for IO from preclinical to clinical stages

  • How can we best incorporate pharmacodynamic biomarkers to guide clinical strategy?
  • What approaches represent the future of predictive biomarkers in the IO space?
  • How can we best design clinical biomarker studies to drive better reverse translation?

Dr. Dan Felitsky is currently President and CSO at Sfida Ventures, where he heads R&D efforts to develop novel oncology medicines. Prior to Sfida Ventures, Dan was VP of Immuno-Oncology at TigaTx, developing a novel class of IgA-based neutrophil-driven therapeutics, and head of Discovery Research at Pyxis Oncology, establishing the company’s scientific team and building through a successful IPO. He also led the Translational Science Platform at Jounce Therapeutics, originating a program partnered with Gilead for $805 million. As a scientific leader, Dan has contributed to over 40 preclinical programs, 8 INDs, and multiple clinical programs. Dan began his industry career at GlaxoSmithKline after a postdoctoral fellowship at Scripps Research. Dan holds a Ph.D. in Biochemistry from the University of Wisconsin-Madison and a B.S. in Cell and Molecular Biology from the Pennsylvania State University.

16:35 – 17:35
Evening Drinks Reception


Immuno-Oncology Xchange | Boston 2024